Novel methods
AssigneeIntra-Cellular Therapies, Inc.
InventorsKimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
Life of this patent
Estimating the term…
Abstract
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Claims19
1-30. (canceled)
A method for the treatment of schizophrenia comprising administering to a patient in need thereof an effective amount of a Compound of Formula I:
- wherein:
- X is —N(CH3)— and Y is —C(O)—;
- in free or pharmaceutically acceptable salt form
- wherein the method improves the negative symptoms of schizophrenia.
A method for the treatment of schizophrenia comprising administering to a patient in need thereof an effective amount of a Compound of Formula I:
- wherein:
- X is —N(CH3)— and Y is —C(O)—;
- in free or pharmaceutically acceptable salt form,
- wherein the method does not result in hyperprolactinemia, EPS/akathisia, weight gain or cardiovascular side effects.
A method for the treatment of schizophrenia comprising administering to a patient in need thereof an effective amount of a Compound of Formula I:
- wherein:
- X is —N(CH3)— and Y is —C(O)—;
- in free or pharmaceutically acceptable salt form,
- wherein the patient has co-morbid depression.
Dependencies are inferred from the claim text.